In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 1-9, 14, 19, and 30 without prejudice to their presentation in another application, and amend claims 26-30 as follows:

1-20. (canceled).

21. (previously presented) A compound which is

(±)-7-methyl-2-morpholin-4-yl-9-(l-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one,

(±)-2-({l-[7-methyl-2-(morpholin4-yl)-4-oxo-pyrido[l,2-a]pyrimidin-9-yl]ethyl} amino)benzoic acid,

(±)-2-({l-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[l,2-a]pyrimidin-9-yl]ethyl}amino)benzonitrile,

(±) methyl 2-({l-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoate, or

(±)-7-methyl-2-(morpholin-4-yl)-9-(l-{[2-(2*H*-tetrazol-5-yl)phenyl]amino}ethyl)-pyrido[l,2-a]pyrimid-4-one.

22-25. (canceled).

26. (currently amended) A compound according to formula (I):



(I)

wherein[[,]] :

R is H, C_1-C_6 branched or straight chain alkyl, [[or]] aryl, or $(CH_2)_n$-aryl;

R_1 is H, OH, OCH_3, OCF_3, F, C1, CF_3, C_1-C_6 branched or straight chain alkyl, [[or]] aryl, or $(CH_2)_n$-aryl;

R_2 is C_1-C_6 branched or straight chain alkyl, [[or]] aryl, or $(CH_2)_n$-aryl in either the R or the S configuration;

R_3 is one or more of H, F, Cl, Br, I, CN, CO_2H, CO_2R, NO_2, CF_3, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, OCH_3, OCH_2F, $OCHF_2$, OCF_3, OR, OSO_2-aryl, substituted or unsubstituted amine, NHCOR, $NHSO_2R$, CONHR, or SO_2NHR;

X is C or N; and

Y is N ~~or O~~.

27. (currently amended) A method for ~~inhibiting phosphoinositide 3-kinase, preventing or~~ treating cardiovascular disease~~, preventing or treating respiratory disease, preventing or treating cancer, or preventing or treating disease linked to disordered white blood cell function,~~

comprising administering an effective amount of ~~any one of the compounds~~ a compound of claim 26 to a patient in need thereof.

28. (currently amended) ~~The~~ A method of ~~claim 27,~~ treating cardiovascular disease comprising administering the 2-morpholino-substituted derivative of formula (I) wherein:



(I)

R is H, C_1-C_6 branched or straight chain alkyl, or aryl;

R_1 is H, OH, OCH_3, OCF_3, F, Cl, CF_3, or C_1-C_6 branched or straight chain alkyl;

R_2 is C_1-C_6 branched or straight chain alkyl, or aryl in either the R or the S configuration;

R_3 is one or more of H, F, Cl, Br, CN, CO_2H, CO_2R, NO_2, CF_3, branched or straight chain C_1-C_6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, OCH_3, OCH_2F, $OCHF_2$, OCF_3, OR, substituted or unsubstituted amine, NHCOR, $NHSO_2R$, CONHR, or SO_2NHR;

X is C or N; and

Y is N ~~or O~~.

29. (currently amended) The method of claim 27, wherein the inhibitor administered is selected from the group consisting of:

(±)-7-methyl-9-{[methyl(phenyl)amino]methyl}-2-morpholin-4-yl-pyrido[l,2-a]pyrimidin-4-one (TGX-195);

(±)-7-methyl-2-morpholin-4-yl-9-(l-phenylaminoethyl)-pyrido[l,2-a]pyrimidin-4-one (TGX-221);

(±)-7-methyl-2-morpholin-4-yl-9-[1-(4-fluorophenylamino)ethyl]-pyrido [1,2-a]pyrimidin-4-one (TGX-224);

(±)-9-[1 -(3,4-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-237);

(±)-9-[l-(2,5-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[l,2-a]pyrimidin-4-one (TGX-238);

(±)-9-[l-(3,5-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[l,2-a]pyrimidin-4-one (TGX-239);

(±)-9-[1-(4-fluoro-2-methylphenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-240);

(±)-9-[l-(4-chlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[l,2-a]pyrimidin-4-one (TGX-243);

(±)-9- [1-(3,4-dichlorophenylamino)ethyl] -7-methyl-2-morpholin-4-yl-pyrido [1,2-a]pyrimidin-4-one (TGX-244);

(±)-9-[l-(3fluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[l,2-a]pyrimidin-4-one (TGX-247);

(±)-9-[l-(3-chlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[l,2-a]pyrimidin-4-one (TGX-248);

~~(±) 7-methyl-2-morpholin-4-yl-9-[1-(2-thiazolylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-261);~~

(±)-7-methyl-9-[l-(3-methylphenylamino)ethyl]-2-morpholin-4-yl-pyrido[l,2-a]pyrimidin-4-one (TGX-262);

(±)-7-methyl-2-morpholin-4-yl-9-[1-(3-trifluoromethylphenylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-264); [[and]]

(±)-7-methyl-2-morpholin-4-yl-9-[l-(2-pyridinylamino)ethyl]-pyrido[l,2-a]pyrimidin-4-one (TGX-295)[[.]] ;

(±)-2-({l-[7-methyl-2-(morpholin4-yl)-4-oxo-pyrido[l,2-a]pyrimidin-9-yl]ethyl} amino)benzoic acid (KN-309);

(±) methyl 2-({ l-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[l ,2-a]pyrimidin-9-yl]ethyl}amino)benzoate (KN-321);

~~(±) 2-({1 - [7-methyl-2-(morpholi-4-yl)-4-oxo-pyrido [1,2-a]pyrimidin-9-yl] ethyl} amino)benzonitrile (KN-320);~~

(±)-2-({1 - [7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido [1,2-a]pyrimidin-9-yl] ethyl} amino)benzonitrile (KN-320);

(±)-7-methyl-2-(morpholin-4-yl)-9-(1-{[2-(2*H*-tetrazol-5 -yl)phenyl] amino} ethyl)-pyrido[1,2-a]pyrimid-4-one (KN-325); and

(±)-2-(4-morpholinyl)-8 [1-(phenylamino)ethyl] -4H-1 -benzopyran-4-one (TGX-280).

30. (canceled).